Flash | 19 Jun 2025 06:54:28 ET │ 16 pages China Materials 2025 On-ground Demand Monitor Series #89 – Aluminum Inventory and Consumption CITI'S TAKE In this series of notes, we aim to track and analyze high-frequency on- ground demand trends in China – market expectation on demand recovery has been largely cautious. In this note, we enclose weekly data from Mysteel, a consultant, on China aluminum ingot and billet production, inventory, and apparent consumption data during the week of 12th to 18th Jun 2025. ...

Core Viewpoint - Momentum investing focuses on "buying high and selling higher" rather than traditional strategies of "buying low and selling high" [1] Group 1: Momentum Investing Strategy - Momentum investors often face challenges in determining the right entry point, as stocks may lose momentum when their valuations exceed future growth potential [2] - Investing in bargain stocks that have recently shown price momentum can be a safer strategy, utilizing tools like the Zacks Momentum Style Score to identify potential opportunities [3] Group 2: ODP Corp. Analysis - ODP Corp. has shown a price increase of 0.3% over the past four weeks, indicating growing investor interest [4] - The stock has gained 11.8% over the past 12 weeks, with a beta of 1.32, suggesting it moves 32% higher than the market [5] - ODP has a Momentum Score of A, indicating a favorable time to invest based on momentum [6] - The stock has received a Zacks Rank 1 (Strong Buy) due to upward revisions in earnings estimates, which attract more investors [7] - ODP is trading at a low Price-to-Sales ratio of 0.07, meaning investors pay only 7 cents for each dollar of sales, indicating a reasonable valuation [7] Group 3: Additional Investment Opportunities - Besides ODP, there are other stocks that meet the criteria of the 'Fast-Paced Momentum at a Bargain' screen, suggesting further investment opportunities [8] - Investors can explore over 45 Zacks Premium Screens tailored to different investing styles to identify potential winning stocks [9]

Core Viewpoint - Gilead Sciences has shown strong performance in 2023 despite recent setbacks, with stock up 18% compared to the S&P 500's 2% gain, and is focused on resolving clinical trial issues while improving profitability [2][3]. Financial Performance - Gilead's stock valuation is around $110 per share, indicating potential for growth [3]. - Revenue growth has been marginal, with a 4.7% increase over the last 12 months from $27 billion to $29 billion, compared to the S&P 500's 5.5% growth [5]. - Quarterly revenues recently shrank by 0.3% to $6.7 billion year-over-year, while the S&P 500 improved by 4.8% [5]. - Gilead's operating income over the last four quarters was $11 billion, yielding a high operating margin of 37.4% [5]. - Net income for the last four quarters was $6.0 billion, resulting in a net income margin of 20.8% [6]. Valuation Metrics - Gilead's Price-to-Sales (P/S) ratio is 4.8, compared to the S&P 500's 3.1 [5]. - The Price-to-Earnings (P/E) ratio for Gilead is 23.2, while the S&P 500 stands at 26.9 [5]. - Gilead's Price-to-Free Cash Flow (P/FCF) ratio is 14.0, significantly lower than the S&P 500's 20.9 [5]. Financial Stability - Gilead's balance sheet is strong, with a Debt-to-Equity Ratio of 18.1% compared to the S&P 500's 19.4% [9]. - Cash and cash equivalents amount to $7.9 billion, representing a Cash-to-Assets Ratio of 14.0% [9]. Downturn Resilience - Gilead stock has historically shown greater resilience during market downturns, with a smaller peak-to-trough decline compared to the S&P 500 during various crises [7][9].

Intel Corporation (NASDAQ: INTC ) has continued to tread water the last few months as an uncertain product timeline, governance upheaval, and looming layoffs have kept investors wary despite bullish overall market sentiment. Even with these roadblocks, Intel's valuation remains attractive, and the company looksTo follow me click the "Follow" button! (Easy right?) Hi there, thanks for coming to my profile page! My name is Kumquat Research (but you can call me Jeremy) and I've been writing for Seeking Alpha o ...

CHONGQING, CHINA - APRIL 20: In this photo illustration, the logo of Boston Scientific Corporation ... More is displayed on a smartphone screen, with the company's branding and slogan Advancing science for life in the background, representing the American biomedical and biotechnology engineering firm known for developing medical devices used in interventional medical specialties, on April 20, 2025, in Chongqing, China. (Photo by Cheng Xin/Getty Images)Getty Images Boston Scientific (NYSE:BSX) has experience ...

Group 1 - GigaCloud Technology Inc. (NASDAQ: GCT) is viewed with caution due to its stock performance, which has been described as decent but requires careful consideration [1] - The article emphasizes the importance of taking the stock with a pinch of salt, indicating potential volatility or uncertainty in its future performance [1]

Core Insights - Insmed Inc experienced a significant stock surge of 45% in the last month, driven by successful Phase IIb trial results for its inhalation therapy TPIP in pulmonary arterial hypertension (PAH) [2] - The company is currently trading at a high valuation of 35 times sales, which translates to a low sales yield of 2.8%, raising concerns about its sustainability [3] - Insmed's stock premium is primarily attributed to the positive trial results and a $750 million capital raise aimed at pipeline expansion, leading to investor optimism [4][5] Financial Performance - Insmed projects global revenues for its product ARIKAYCE to be between $405 million and $425 million in 2025, indicating an 11-17% growth compared to 2024 [6] - The company is expected to remain unprofitable into 2026 due to ongoing investments in research and development for pipeline products [6] Future Outlook - The FDA's decision on brensocatib in August and the initiation of Phase 3 trials for TPIP are critical upcoming milestones that could significantly impact Insmed's stock performance [7] - Successful execution of Phase 3 trials and commercial launches of both brensocatib and TPIP will be essential for maintaining the current premium valuation [7][8]

MicroStrategy (MSTR) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this business software company have returned -4.4%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Computer - Software industry, which MicroStrategy falls in, has gained 6.9%. The key question now is: What could be the stock's f ...

Agnico Eagle Mines (AEM) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.Over the past month, shares of this gold mining company have returned +14.6%, compared to the Zacks S&P 500 composite's +3.6% change. During this period, the Zacks Mining - Gold industry, which Agnico falls in, has gained 13%. The key question now is: What could be the stock's future direction?Although media repor ...

Core Viewpoint - Boeing's stock is currently viewed as unattractive due to poor operational performance and financial health, despite a seemingly reasonable valuation of approximately $205 [3][13]. Financial Performance - Boeing's revenues have declined by 9.2% from $76 billion to $69 billion in the past 12 months, contrasting with a 5.5% growth for the S&P 500 [11] - The company's operating income over the last four quarters was -$10 billion, resulting in an operating margin of -14.7%, compared to 13.2% for the S&P 500 [11] - Boeing's net income for the last four quarters was -$12 billion, leading to a net income margin of -16.6%, while the S&P 500 had a margin of 11.6% [11] Valuation Metrics - Boeing has a price-to-sales (P/S) ratio of 2.3, which is lower than the S&P 500's ratio of 3.0 [5]. - The stock has fallen 57.0% from a high of $269.19 on March 12, 2021, to $115.86 on June 13, 2022, compared to a peak-to-trough decline of 25.4% for the S&P 500 [12]. Growth and Profitability - Boeing's top line has increased at an average rate of 4.9% over the last three years, compared to a 5.5% rise for the S&P 500 [11]. - Boeing's profit margins are significantly lower than most companies in the Trefis coverage universe, indicating extremely weak profitability [7][15]. Financial Stability - Boeing's total debt was $54 billion at the end of the most recent quarter, with a market capitalization of $154 billion, resulting in a high debt-to-equity ratio of 32.9% compared to 19.9% for the S&P 500 [11]. - Cash and cash equivalents account for $24 billion of Boeing's total assets of $156 billion, leading to a moderate cash-to-assets ratio of 15.1% [11]. Downturn Resilience - Boeing's stock has performed significantly worse than the S&P 500 during recent downturns, indicating extremely weak resilience [9][15]. - The stock has not yet recovered to its pre-crisis peak, highlighting ongoing challenges [12].